leadf
logo-loader
NASDAQ:ALNY

Alnylam Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$22.27 billion
Price
187.40 USD
Change
0.24%
52 weeks high
209.53
52 weeks low
119.53

In brief

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection.